AGIO

Tibsovo (Ivosidenib )

Acute Myeloid Leukemia (AML) with IDH1 mutation

Stage (next event)

Expected Date

Quarterly Sales (Approved)

February 12, 2021 (Est)

Catalyst Info & Data Links

TITLE: Tibsovo (Ivosidenib ) for Acute Myeloid Leukemia (AML) with IDH1 mutation Quarterly Sales (Approved)


WHAT IS THE NEXT CATALYST EVENT?

  • Quarterly Sales (Approved)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 12, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION 

  • TIBSOVO targets the mutant IDH1 enzyme to restore myeloid differentiation

  • Source (Here)

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon